Quince Therapeutics, Inc.

Price Chart

Risk-Adjusted Performance

Quince Therapeutics, Inc. (QNCX) Price Performance

Quince Therapeutics, Inc. (QNCX) trades on United States in USD. The company is classified in the Healthcare sector under the Biological Products industry. The stock currently trades at $1.36, down 0.73% from the previous close.

Over the past year, QNCX has traded between a low of $0.08 and a high of $4.40. The stock has gained 10.6% over this period. It is currently 69.1% below its 52-week high.

Quince Therapeutics, Inc. has a market capitalization of $6.89M.

About Quince Therapeutics, Inc.

Quince Therapeutics, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene. Its AIDE technology platform, a drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells, as well as consists of an automated equipment the RCL, a sterile single-use consumable treatment kit comprising kit medical devices, syringe kit, and process solutions. The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August 2022. The company was incorporated in 2012 and is headquartered in South San Francisco, California.

Compare Quince Therapeutics, Inc.

Side-by-side comparison against top Healthcare peers.